Anti-HPV16E7 protein monoclonal antibody 69A6, hybridoma cells, and preparation method and application of anti-HPV16E7 protein monoclonal antibody 69A6
By developing the anti-HPV16E7 protein monoclonal antibody 69A6 and its hybridoma cells, we have solved the diagnostic difficulties in the existing technology when HR-HPV DNA is positive, achieved high-sensitivity detection of early-stage cervical cancer, and reduced the burden of examinations.
Patent Information
- Application Number
- CN202010179913.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2020-03-16
- Publication Date
- 2020-06-26
- Estimated Expiration
- 2040-03-16
AI Technical Summary
Existing cervical cancer screening methods lack clear treatment plans when HR-HPV DNA tests are positive, resulting in the trauma and psychological and economic burden of colposcopy, and are unable to early warn and diagnose cervical cancer, especially in CIN1, CIN2, and CIN3 Wait for the early stages.
Developed the anti-HPV16E7 protein monoclonal antibody 69A6 and its hybridoma cells. Through hybridoma technology screening and purification, high-titer monoclonal antibodies were obtained for quantitative detection of HPV16E7 protein, preparation of ELISA kits, etc., achieving specificity for HPV16E7 protein. Highly accurate and sensitive detection.
This technology can provide important significance in the early diagnosis of cervical cancer. Through highly sensitive and specific detection, it helps to detect cervical cancer cells early, reducing unnecessary examination frequency and patient burden.
